A Phase 3 study found that once-weekly insulin efsitora was as effective and safe as daily insulin glargine for people with type 2 diabetes. The findings were reported at the American Diabetes Association’s 85th Scientific Sessions and in The New England Journal of Medicine.
Full Story: MedPage Today (free registration) (6/22)